Daily Equity Reports 26 Dec 2018

1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 26th DECEMBER 2018 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET CLOSE PREVIOUS ! 35470.15 INDIAN EQUITY BENCHMARK :- At the close of market hours, the Sensex was down 271.92 points or 0.76% at 10663.50 35470.15, while the Nifty was lower by 90.50 points or 0.84% at ASIAN MARKET 10663.50. The market breadth was negative as 908 shares CLOSE PREVIOUS advanced, against a decline of 1,638 shares, while 142 shares NIKKEI 20166.19 were unchanged. GLOBAL FACE 25651.38 2061.49 ! SECTORIAL INDICES Asian Market - Asian markets finished mixed as of the most recent closing prices. The Shanghai Composite gained 0.43%, while the Nikkei 225 led the Hang Seng lower. They fell 1.11% and 0.40% respectively. CLOSE CHANGE (%) 10904.70 -0.92 -0.88 ! U.S. Market – Dow dives 400 points to end its worst week in 10 years. -0.59 ! -0.89 European markets - European markets are lower today as French .BANK NIFTY 26714.75 -0.58 and British shares fall. The French CAC 40 is off 1.09% while the London FTSE 100 is down 0.44%. The German DAX is not trading. CLOSE CHANGE (%) INFRATEL 1.94 1.38 WIPRO 1.23 M&M 0.90 TOP LOSERS CLOSE CHANGE (%) JSWSTEEL -5.16 -4.76 -3.11 BAJAJ AUTO 2728.00 -2.86 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE TREND STRATEGY SCRIPT CLOSE (%) 3.75 BEARISH 2.46 P R1 R2 10831 RESISTANCE R1-10830 R2-10960 R3 10964 10432 10565 10614 10698 10747 1275.90 2.04 APOLLOHOSP SUPPORT S1-10560 S2-10430 1.93 CLOSE (%) -4.88 JSWSTEEL -4.47 3173.05 -4.42 MOTHERSU -4.03 TREND BULLISH NET (CR.) S3 S2 S1 26704 P R1 R2 R3 26353 26598 26843 26949 1732.56 SUPPORT S1-26700 S2-26350 RESISTANCE DII 2076.76 BANK NIFTY NSE TOTALS ADVANCE Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report MARKET TALKS ! ! Dr.Reddys launches gAggrenox in US Dr.Reddy's Laboratories, in a filing to the exchanges on Monday, informed that the company, along with its subsidiaries, launched aspirin and dipyridamole capsules in the US markets. The capsules are the therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules, the company added. Hero MotoCorp under pressure after ratings downgrade; stock down ~4% Shares of Hero MotoCorp (HMCL) dropped ~4% on the BSE after global brokerage house Goldman Sachs downgraded the stock to sell from neutral. The stock was the top loser on the Nifty Auto index.The brokerage firm slashed its target price sharply by 12.66% from Rs3,175 to Rs2,773, implying a 16.5% potential downside from December 21 closing levels, as per a media report.Goldman Sachs believes near-term volumes and results will be muted, the report added. Reliance Industries acquires stake in Vakt Holdings Reliance Industries in its filing to the exchanges on Monday informed that the company has acquired 5.56% stake in Vakt Holdings Limited (UK) for cash aggregating $5mn."No regulatory approvals were required for the said acquisition of shares. The investment does not fall within related party transactions and none of RIL's promoter/promoter group/group companies have any interest in VHL," the company said in a press note to the exchanges.VHL is a consortium of global energy majors, commodity traders, and banks to digitize the global commodities trading industry, the company added. extended-release ! ! Cadila gets USFDA nod for Doxycycline Hyclate Delayed-Release Tablets Zydus Cadila, in a filing to the exchanges on Monday, informed that it has received approval from the USFDA to market Doxycycline Hyclate Delayed-Release Tablets USP (US RLD-Doryx) in the strengths of 75mg, 100mg, and 150mg. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report STOCK TO WATCH TOMORROW :- NAME OF THE STOCK : SRF DATE : 24/12/2018 SEGMENT : CASH CHART :- TYPE OF ADVICE: SELL SRF IN CASH BELOW 1960 TGT 1880 SL 2040 RATIONALE FOR ARRIVING INVESTMENT ADVICE : TECHNICAL VIEW : THE STOCK TECHINCALLY IS DOWN, SHOWING MONTHLY AND WEEKLY REVERSAL AS WELL AS BREAKOUT IN DAILY CHART AND TAKING SUPPORT OF ALL MAJOR INDICATORS INCLUDING MACD,MOVING AVERAGES,VOLUME AND RSI FACTOR. OTHER REASONS IF ANY :- SUPPORT IS BREAKEN TODAY WITH HEAVY VOLUME AND SHOWING WEAKNESS IN INTRADAY CHARTS. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. Capitalstars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Intraday stock tips Financial advisory company Share market company Stock Tips * Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. * CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

8. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.com Contact no :- 9977499927, 9039012727 Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.